BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: BeOne Medicines (ONC) is conducting a Phase 1a/b study titled A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors. The study aims to evaluate the safety and preliminary antitumor activity of BG-C137 in patients with advanced solid tumors, marking a significant step in oncology treatment research.
Intervention/Treatment: The study tests BG-C137, an antibody-drug conjugate administered intravenously, designed to target FGFR2b in advanced solid tumors, aiming to assess its safety and effectiveness as a potential cancer treatment.
Study Design: This interventional study is non-randomized with a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused, evaluating BG-C137 across different dose levels.
Study Timeline: The study began on September 23, 2024, with the latest update on October 9, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is vital for stakeholders tracking its development.
Market Implications: The ongoing study of BG-C137 could influence BeOne Medicines’ stock performance positively if results show promising safety and efficacy. Investors should watch for updates, as successful outcomes could enhance the company’s competitive position in the oncology market, potentially affecting investor sentiment and market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.